Project Grant R01CA306009
Award Date 7/1/26
Completion Date 6/30/31
Dollars Obligated $688K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Dallas, TX 75390, USA
Similar Awards
- Federal Grant Award Summary The University of Texas Southwestern Medical Center received a $682,969 Project Grant from the National Cancer Institute (NCI) under the Cancer Biology Research program (CFDA 93.396), effective July 1, 2026, through June 30, 2031. This award supports fundamental research into the hormonal regulation of myeloid immune checkpoint mechanisms within the tumor microenvironment (TME). The project investigates how Secretogranin II (SCG2), a hormone overexpressed in breast...
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded a $639,514 Project Grant under the Cancer Biology Research program (CFDA 93.396) to The University of Texas Southwestern Medical Center, effective June 1, 2026, through May 31, 2031. This five-year research initiative focuses on characterizing the mechanistic basis of NVL (Nuclear VCP-Like) inhibition by benzothiazepinone compounds—specifically MM17—as a novel non-genotoxic chemotherapy strategy. The research delivers...
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded The University of Texas Southwestern Medical Center a $596,501 Project Grant under the Cancer Biology Research program (CFDA 93.396) on June 20, 2026, with a completion date of May 31, 2031. This award funds fundamental research to investigate the molecular mechanisms of translocation renal cell carcinoma (TRCC), a rare and aggressive pediatric kidney cancer subtype characterized by chromosomal translocations in...
- Federal Project Grant Award Summary The University of Texas Southwestern Medical Center received a $501,803 Project Grant award from the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395) effective June 1, 2026, through May 31, 2031. This research project focuses on decoding the stromal microenvironment of pancreatic ductal adenocarcinoma (PDAC) by elucidating the role of antigen-presenting cancer-associated fibroblasts (APCAFs) in tumor progression and...
- Federal Grant Award Summary The National Cancer Institute awarded a $404,972 Project Grant to The University of Texas Health Science Center at San Antonio under the Cancer Biology Research program (CFDA 93.396) for a two-year project period beginning August 1, 2025 and concluding July 31, 2027. This award supports fundamental research investigating ribosomal ribonucleic acid (rRNA) modification, ribosome composition, and specialized translation mechanisms in glioblastoma, the most common and...
- Federal Project Grant Award Summary The University of Texas Southwestern Medical Center received a $376,886 Project Grant from the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395) for the period July 1, 2026 through June 30, 2029. The award supports the development of novel small-molecule inhibitors targeting Site-One Protease (S1P) to prevent and treat cancers, particularly clear cell renal cell carcinoma and hepatocellular carcinoma. The research builds...
- Federal Project Grant Award Summary The National Cancer Institute (NCI), under the Cancer Biology Research program (CFDA 93.396), awarded a $388,546 Project Grant to the University of Texas Health Science Center at Houston effective June 1, 2026, through May 31, 2031. The research project, "Targeting the Golgi Secretory Pathway in Chromosome 3Q-Amplified Human Cancer," addresses a significant gap in targeted therapies for non-small cell lung cancers (NSCLC) lacking actionable mutations...
- Federal Grant Award Summary The National Cancer Institute awarded The University of Texas Southwestern Medical Center a $688,012 Project Grant under the Cancer Treatment Research program (CFDA 93.395) on June 1, 2026, with a completion date of May 31, 2031. This award supports the development of novel RPS23 (ribosomal protein S23) inhibitors for the treatment of acute myeloid leukemia (AML). The research leverages an integrated platform combining high-throughput phenotypic screening with rapid...
- Federal Project Grant Award Summary The University of Texas Southwestern Medical Center received a $426,828 Project Grant award from the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395), effective June 1, 2026, through May 31, 2028. The grant supports research targeting epigenetic vulnerabilities in osteosarcoma to enhance immunotherapy outcomes in pediatric patients. The research integrates two complementary approaches: (1) development of novel...
- Federal Project Grant Award Summary The University of Texas Southwestern Medical Center received a $683,885 Project Grant from the National Cancer Institute under the Cancer Treatment Research program (CFDA 93.395), awarded May 1, 2026, with completion targeted for April 30, 2031. The project develops the first clinical prototype for proton minibeam radiation therapy (PMBRT), an advanced spatially fractionated radiation therapy modality designed to enhance therapeutic efficacy by delivering...